288 related articles for article (PubMed ID: 22477069)
1. Combining cheminformatics methods and pathway analysis to identify molecules with whole-cell activity against Mycobacterium tuberculosis.
Sarker M; Talcott C; Madrid P; Chopra S; Bunin BA; Lamichhane G; Freundlich JS; Ekins S
Pharm Res; 2012 Aug; 29(8):2115-27. PubMed ID: 22477069
[TBL] [Abstract][Full Text] [Related]
2. Combining Metabolite-Based Pharmacophores with Bayesian Machine Learning Models for Mycobacterium tuberculosis Drug Discovery.
Ekins S; Madrid PB; Sarker M; Li SG; Mittal N; Kumar P; Wang X; Stratton TP; Zimmerman M; Talcott C; Bourbon P; Travers M; Yadav M; Freundlich JS
PLoS One; 2015; 10(10):e0141076. PubMed ID: 26517557
[TBL] [Abstract][Full Text] [Related]
3. Validating new tuberculosis computational models with public whole cell screening aerobic activity datasets.
Ekins S; Freundlich JS
Pharm Res; 2011 Aug; 28(8):1859-69. PubMed ID: 21547522
[TBL] [Abstract][Full Text] [Related]
4. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
5. Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis.
Ekins S; Kaneko T; Lipinski CA; Bradford J; Dole K; Spektor A; Gregory K; Blondeau D; Ernst S; Yang J; Goncharoff N; Hohman MM; Bunin BA
Mol Biosyst; 2010 Nov; 6(11):2316-2324. PubMed ID: 20835433
[TBL] [Abstract][Full Text] [Related]
6. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening.
Manjunatha UH; Smith PW
Bioorg Med Chem; 2015 Aug; 23(16):5087-97. PubMed ID: 25577708
[TBL] [Abstract][Full Text] [Related]
7. Informatics resources for tuberculosis--towards drug discovery.
Sundaramurthi JC; Brindha S; Reddy TB; Hanna LE
Tuberculosis (Edinb); 2012 Mar; 92(2):133-8. PubMed ID: 21943870
[TBL] [Abstract][Full Text] [Related]
8. New approaches to tuberculosis--novel drugs based on drug targets related to toll-like receptors in macrophages.
Tomioka H
Curr Pharm Des; 2014; 20(27):4404-17. PubMed ID: 24245765
[TBL] [Abstract][Full Text] [Related]
9. The Mycobacterium tuberculosis drugome and its polypharmacological implications.
Kinnings SL; Xie L; Fung KH; Jackson RM; Xie L; Bourne PE
PLoS Comput Biol; 2010 Nov; 6(11):e1000976. PubMed ID: 21079673
[TBL] [Abstract][Full Text] [Related]
10. An
Kumar S; Sahu P; Jena L
Int J Mycobacteriol; 2019; 8(3):252-261. PubMed ID: 31512601
[TBL] [Abstract][Full Text] [Related]
11. Machine learning and docking models for Mycobacterium tuberculosis topoisomerase I.
Ekins S; Godbole AA; Kéri G; Orfi L; Pato J; Bhat RS; Verma R; Bradley EK; Nagaraja V
Tuberculosis (Edinb); 2017 Mar; 103():52-60. PubMed ID: 28237034
[TBL] [Abstract][Full Text] [Related]
12. In silico analyses for the discovery of tuberculosis drug targets.
Chung BK; Dick T; Lee DY
J Antimicrob Chemother; 2013 Dec; 68(12):2701-9. PubMed ID: 23838951
[TBL] [Abstract][Full Text] [Related]
13. In silico discovery and virtual screening of multi-target inhibitors for proteins in Mycobacterium tuberculosis.
Speck-Planche A; Kleandrova VV; Luan F; Cordeiro MN
Comb Chem High Throughput Screen; 2012 Sep; 15(8):666-73. PubMed ID: 22452349
[TBL] [Abstract][Full Text] [Related]
14. Computational models for tuberculosis drug discovery.
Ekins S; Freundlich JS
Methods Mol Biol; 2013; 993():245-62. PubMed ID: 23568475
[TBL] [Abstract][Full Text] [Related]
15. A collaborative database and computational models for tuberculosis drug discovery.
Ekins S; Bradford J; Dole K; Spektor A; Gregory K; Blondeau D; Hohman M; Bunin BA
Mol Biosyst; 2010 May; 6(5):840-51. PubMed ID: 20567770
[TBL] [Abstract][Full Text] [Related]
16. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
17. Systems level mapping of metabolic complexity in Mycobacterium tuberculosis to identify high-value drug targets.
Vashisht R; Bhat AG; Kushwaha S; Bhardwaj A; ; Brahmachari SK
J Transl Med; 2014 Oct; 12():263. PubMed ID: 25304862
[TBL] [Abstract][Full Text] [Related]
18. Increasing the structural coverage of tuberculosis drug targets.
Baugh L; Phan I; Begley DW; Clifton MC; Armour B; Dranow DM; Taylor BM; Muruthi MM; Abendroth J; Fairman JW; Fox D; Dieterich SH; Staker BL; Gardberg AS; Choi R; Hewitt SN; Napuli AJ; Myers J; Barrett LK; Zhang Y; Ferrell M; Mundt E; Thompkins K; Tran N; Lyons-Abbott S; Abramov A; Sekar A; Serbzhinskiy D; Lorimer D; Buchko GW; Stacy R; Stewart LJ; Edwards TE; Van Voorhis WC; Myler PJ
Tuberculosis (Edinb); 2015 Mar; 95(2):142-8. PubMed ID: 25613812
[TBL] [Abstract][Full Text] [Related]
19. Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery.
Ekins S; Freundlich JS; Hobrath JV; Lucile White E; Reynolds RC
Pharm Res; 2014 Feb; 31(2):414-35. PubMed ID: 24132686
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel lysine ɛ-aminotransferase inhibitors: An intriguing potential target for latent tuberculosis.
Devi PB; Sridevi JP; Kakan SS; Saxena S; Jeankumar VU; Soni V; Anantaraju HS; Yogeeswari P; Sriram D
Tuberculosis (Edinb); 2015 Dec; 95(6):786-794. PubMed ID: 26299907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
